28 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
that are expected to be exercised. Fair value is measured by use of the Black & Scholes model. The expected life used in the model has been adjusted, based … ’ and are either made synthetically or purified from plants Black & Scholes model A mathematical description of financial markets and derivative investment
6-K
EX-99.2
GLPG
Galapagos NV
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
a product candidate has a biological effect Black & Scholes model A mathematical description of financial markets and derivative investment
6-K
EX-99.2
GLPG
Galapagos NV
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
, particularly to determine whether a Bispecific antibody An antibody that binds to two different antigens Black & Scholes model widely A mathematical used
6-K
EX-99.2
GLPG
Galapagos NV
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
to determine whether a
Bispecific antibody
An antibody that binds to two different antigens
Black & Scholes model
A widely mathematical used
6-K
EX-99.2
em5b1p
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.2
6vlwwo5rezv
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.2
putw6jmocdm
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.2
mtf17djc2
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
pxa19462wh26gx8s uua
21 Jan 21
Current report (foreign)
7:49am
6-K
EX-99.2
on2elk5bh
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.2
kls9m
6 Aug 20
Galapagos reports solid H1 2020 progress
4:01pm
6-K
EX-99.2
pk83yne3yyq3ls qs
11 May 20
Current report (foreign)
4:05pm
6-K
EX-99.2
e37gqs6
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99
m3m 40vmgeyu6b
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm